As is the case with mesothelin, several approaches to targeting this protein for advanced solid tumors, including mesothelioma, are being explored; however, in contrast to mesothelin, it is also highly expressed in sarcomatoid tumors and represents a promising target for future therapy. The gene discussed is MSLN; the disease is mesothelioma.